


CLAIMS

1- Compound of the formula I:



5 in which

A and B independently represent an optionally substituted phenyl nucleus;
or an optionally substituted pyridyl nucleus;

T represents an optionally substituted, saturated and/or unsaturated aromatic carbocyclic nucleus; an optionally substituted, saturated and/or unsaturated
10 aromatic heterocyclic nucleus; or

T represents a saturated and/or unsaturated aromatic carbocyclic nucleus which is fused to the nucleus A, is optionally substituted and is linked to two adjacent carbon atoms belonging to the nucleus A;

R represents a hydrogen atom; an optionally substituted saturated aliphatic
15 hydrocarbon-based group; or an optionally substituted, saturated or unsaturated aromatic carbocyclic group;

n represents an integer chosen between 1, 2, 3, 4 and 5;

the radicals X_i and Y_i are independently chosen from a hydrogen atom; a halogen atom; an optionally substituted, saturated and/or unsaturated aliphatic
20 hydrocarbon-based group; an optionally substituted, saturated or unsaturated aromatic carbocyclic nucleus; a $-u^1-COOL$ group, in which u^1 represents a bond or an alkylene group and L is an optionally substituted saturated aliphatic hydrocarbon-based group or an optionally substituted, saturated and/or unsaturated aromatic carbocyclic group; $-u^2-SiR^1R^2R^3$, in which u^2 represents a bond, an
25 alkylene group or an alkyleneoxy group in which the oxygen atom is linked to Si and R^1 , R^2 and R^3 independently represent an optionally substituted saturated aliphatic hydrocarbon-based group; $-u^3-OW$, in which u^3 represents a bond or an alkylene group and W may represent a hydrogen atom or is as defined above for L; u^4-CO-G , in which u^4 represents a bond, an alkylene group or an alkyleneoxy
30 group in which the oxygen atom is linked to the carbonyl group and G is as

defined above for L; $-u^5-CO-NH-J$, in which u^5 represents a bond, an alkylene group or an alkyleneoxy group in which the oxygen atom is linked to the carbonyl group and J is as defined above for L; or a radical Xi and a radical Yi both attached to the same carbon atom, together with this carbon atom, represent an optionally substituted saturated carbocyclic nucleus;
5 and the pharmaceutically usable derivatives, solvates and stereoisomers thereof comprising a mixture thereof in all proportions.

2- Compound according to Claim 1, in which A and B represent optionally substituted phenyl.

10 3- Compound according to Claim 1, in which B represents optionally substituted phenyl; and A represents optionally substituted pyridyl.

4- Compound according to any one of the preceding claims, characterised in that T represents an optionally substituted monocyclic or bicyclic aryl nucleus; a saturated or unsaturated, monocyclic or bicyclic aromatic heterocyclic nucleus
15 containing 1 to 3 heteroatoms chosen from N, O and S, the said nucleus being optionally substituted by one or more radicals chosen from oxo, a halogen atom, alkyl which is optionally halogenated and/or optionally interrupted by one or more oxygen or sulfur atoms; $-alk^1-O-CO-R^4$, in which alk^1 is an alkylene radical and R^4 represents alkyl or alkylamino; $-alk^2-CO-O-R^5$, in which alk^2 is an alkylene radical and R^5 is as defined above for R^4 ; $-CO-R^6$, in which R^6 is as defined above for R^4 ;
20 hydroxyalkyl; $-alk^3-TT-Q$, in which alk^3 represents alkylene, TT represents O or NH, and Q represents an optionally substituted arylalkyl nucleus; optionally substituted heteroarylalkyl; $-CO-K$, in which K represents alkyl or alkoxy; or $-SO_2-K$ in which K is as defined above; $-alk^4-O-CO-NH-alk^5$, in which $-alk^4$ and alk^5 independently represent alkylene; aminoalkyl; hydroxyalkyl, heteroarylalkyl, preferably imidazolylalkyl; and alkenyl.

5- Compound according to any one of the preceding claims, characterised in that R is chosen from H and alkyl.

6- Compound according to any one of the preceding claims, characterised
30 in that n represents 1, 2 or 3.

7- Compound according to any one of the preceding claims, characterised in that the radicals Xi and Yi are independently chosen from a hydrogen atom; a halogen atom; an alkyl group which is optionally interrupted by one or more

oxygen or sulfur atoms; a hydroxyalkyl group; -COOL, in which L is as defined in Claim 1; -alk³-SiR¹R²R³, in which alk³ represents alkylene and R¹, R² and R³ are as defined in Claim 1; -alk⁴-O-CO-alk⁵, in which alk⁴ and alk⁵ independently represent alkyl; -alk⁶-O-CO-NH-alk⁷, in which alk⁶ and alk⁷ independently represent alkyl.

8- Compound according to any one of the preceding claims, characterised in that A represents phenyl which is optionally substituted by halogen, alkyl or alkoxy, and in that B represents phenyl which is optionally substituted by halogen, alkyl or alkoxy.

10 9- Compound according to any one of the preceding claims, characterised in that A represents pyridyl; B represents phenyl; n represents 1, 2 or 3; R represents H; and the radicals Xi and Yi represent a hydrogen atom or a fluorine atom.

10- Compound according to any one of the preceding claims, characterised in that the radicals Xi and Yi attached to the same carbon atom are identical and both represent a hydrogen atom or both represent a fluorine atom.

11- Compound according to any one of the preceding claims, characterised in that T represents a nucleus chosen from phenyl, pyrrolyl, phthalimidyl and succinimidyl, the said nucleus being optionally substituted by one or more radicals chosen from:

- 20 - alkyl which is optionally halogenated and/or optionally interrupted by one or more oxygen or sulfur atoms;
- alk¹-O-CO-R⁴, in which alk¹ is an alkylene radical and R⁴ represents alkyl or alkylamino;
- alk²-CO-O-R⁵, in which alk² is an alkylene radical and R⁵ is as defined above for R⁴;
- 25 - CO-R⁶, in which R⁶ is as defined above for R⁴;
- hydroxyalkyl;
- heteroarylalkyl, preferably imidazolylalkyl; and
- alkenyl.


30 12- Compound of the formula I according to Claim 1, chosen from:

- 5-(4'-trifluoromethylbiphen-2-ylcarbonylamino)-2,2-difluorobenzo[1,3]-dioxole;
- 5-(4'-isopropylbiphen-2-ylcarbonylamino)-2,2-difluorobenzo[1,3]dioxole;

- 5-(4'-methoxybiphen-2-ylcarbonylamino)-2,2-difluorobenzo[1,3]dioxole;
- 5-(4'-trifluoromethoxybiphen-2-ylcarbonylamino)-2,2-difluorobenzo[1,3]-dioxole;
- 5-(4'-isopropylbiphen-2-ylcarbonylamino)benzo[1,3]dioxole;
- 5 - 5-(4'-ethyl-3-methylbiphen-2-ylcarbonylamino)-2,2-difluorobenzo[1,3]-dioxole;
- 5-(4'-ethylaminocarbonyloxyethylbiphen-2-ylcarbonylamino)-2,2-difluorobenzo[1,3]dioxole;
- 5-(4'-trifluoromethoxy-3-methylbiphen-2-ylcarbonylamino)-2,2-difluorobenzo[1,3]dioxole;
- 10 - 5-(4'-methoxycarbonyl ethylbiphen-2-ylcarbonylamino)-2,2-difluorobenzo[1,3]dioxole;
- 4'-isopropylbiphenyl-2-carboxylic acid (3-methoxymethyl-2,3-dihydrobenzo[1,4]dioxin-6-yl)amide;
- 15 - 7-[(4'-isopropylbiphenyl-2-carbonyl)amino]-2,3-dihydrobenzo[1,4]dioxin-2-ylmethyl ethylcarbamate;
- 4'-ethylbiphenyl-2-carboxylic acid (2,2-difluorobenzo[1,3]dioxol-5-yl)-amide;
- 4'-trifluoromethoxybiphenyl-2-carboxylic acid benzo[1,3]dioxol-5-ylamide;
- 20 - 4'-(2-hydroxyethyl)biphenyl-2-carboxylic acid (2,2-difluorobenzo[1,3]-dioxol-5-yl)amide;
- 4'-isobutylbiphenyl-2-carboxylic acid (2,2-difluorobenzo[1,3]dioxol-5-yl)-amide;
- 4'-(2-methylpropenyl)biphenyl-2-carboxylic acid (2,2-difluorobenzo[1,3]-dioxol-5-yl)amide;
- 25 - 6-chloro-4'-isopropylbiphenyl-2-carboxylic acid (2,2-difluorobenzo[1,3]-dioxol-5-yl)amide;
- 6-chloro-4'-trifluoromethoxybiphenyl-2-carboxylic acid (2,2-difluorobenzo[1,3]dioxol-5-yl)amide;
- 30 - 4'-(2-benzyloxyethyl)-6-methylbiphenyl-2-carboxylic acid (2,2-difluorobenzo[1,3]dioxol-5-yl)amide;
- 6-methoxy-4'-trifluoromethoxybiphenyl-2-carboxylic acid (2,2-difluorobenzo[1,3]dioxol-5-yl)amide;


- 6-methyl-4'-trifluoromethoxybiphenyl-2-carboxylic acid (2-methoxymethyl-2,3-dihydrobenzo[1,4]dioxin-6-yl)amide;
- 6-[(6-methyl-4'-trifluoromethoxybiphenyl-2-carbonyl)amino]-2,3-dihydrobenzo[1,4]dioxin-2-ylmethyl ethylcarbamate;
- 5 - 2-[6'-(2,2-difluorobenzo[1,3]dioxol-5-ylcarbamoyl)-2'-methylbiphenyl-4-yl]-ethyl ethylcarbamate;
- 4'-ethylbiphenyl-2-carboxylic acid benzo[1,3]dioxol-5-ylamide.

13- Process for the preparation of compounds of the formula I as defined in any one of Claims 1 to 12, characterised in that a carboxylic acid of the formula II:



II

10 in which A and T are as defined in any one of Claims 1 to 12, optionally in activated form, is reacted with an amine of the formula III:




III

- 15 in which R, Xi, Yi, n and B are as defined in any one of Claims 1 to 12.

14- Process for the preparation of compounds of the formula I in which R represents an optionally substituted saturated aliphatic hydrocarbon-based group; or an optionally substituted, saturated or unsaturated aromatic carbocyclic group, the said process comprising the reaction of the amino function attached to the
 20 nuclei A and B of the corresponding compound of the formula I in which R represents a hydrogen atom, with a suitable electrophilic site.

15- Compound of the formula XXI a




XXIa

in which (—) denotes the possible substituent(s) on the phenyl group to which (—) is attached, which are chosen from halogen, alkyl and alkoxy.

16- Compound according to Claim 15, for which (—) denotes methyl.

17- Compound of the formula XIVa:




5

in which (—) denotes the possible substituent(s) on the phenyl group to which (—) is attached, which are chosen from halogen, alkyl and alkoxy.

18- Compound according to Claim 17 of the formula XIVa, for which () denotes a hydrogen atom or a methyl group.

10 19- Compound of the formula IIb:



in which

P is chosen from $-\text{OCF}_3$ provided that (—) does not represent hydrogen; $-\text{CO}-\text{CH}(\text{CH}_3)_2$; $-(\text{CH}_2)_2-\text{O}-\text{CO}-\text{CH}_3$; $-(\text{CH}_2)_2-\text{CO}-\text{O}-\text{CH}_3$; and $-(\text{CH}_2)_2-\text{O}-\text{CO}-\text{NH}-\text{CH}_2-\text{CH}_3$;

15

(—) denotes the possible substituent(s) on the phenyl group to which (—) is attached, which are chosen from hydrogen, halogen, such as chlorine, alkyl, such as methyl and alkoxy, such as methoxy.


20- Compound according to Claim 19 of the formula IIb, chosen from:

20

- 6-methyl-4'-trifluoromethoxybiphenyl-2-carboxylic acid;
- 6-methoxy-4'-trifluoromethoxybiphenyl-2-carboxylic acid;
- 6-chloro-4'-trifluoromethoxybiphenyl-2-carboxylic acid;

- 4'-isobutyrylbiphenyl-2-carboxylic acid;
- 4'-(2-acetoxyethyl)biphenyl-2-carboxylic acid;
- 4'-(2-methoxycarbonyl)ethyl)biphenyl-2-carboxylic acid;
- 4'-(2-ethylcarbamoxyloxyethyl)biphenyl-2-carboxylic acid;
- 5 - 4'-(2-ethylcarbamoxyloxyethyl)-6-methylbiphenyl-2-carboxylic acid.

21- Compound of the formula III d:




in which r represents (C₁-C₆)alkyl, preferably methyl, and NH₂ is located in position 6 or 7, with the exclusion of 2-ethoxymethyl-2,3-dihydro-benzo[1,4]dioxin-7-ylamine.

22- Compound according to Claim 21 of the formula III c, chosen from:

- 3-methoxymethyl-2,3-dihydrobenzo[1,4]dioxin-6-ylamine; and
- 2-methoxymethyl-2,3-dihydrobenzo[1,4]dioxin-6-ylamine.

23- Compound of the formula XI a:




in which r represents (C₁-C₆)alkyl, preferably methyl, and NO₂ is located in position 6 or 7, with the exclusion of 2-ethoxymethyl-7-nitro-2,3-dihydro-benzo[1,4]-dioxine.

24- Compound of the formula XI a according to Claim 23, chosen from:

- 20 - 2-methoxymethyl-7-nitro-2,3-dihydrobenzo[1,4]dioxine;
- 2-methoxymethyl-6-nitro-2,3-dihydrobenzo[1,4]dioxine.

25- Compound of the formula III e:




in which R^1 , R^2 and R^3 independently represent (C_1-C_6) alkyl and $-NH_2$ is located in position 6 or 7.

26- Compound of the formula IIIb according to Claim 25, chosen from:

- 3-(*tert*-butyldimethylsilanyloxymethyl)-2,3-dihydrobenzo[1,4]dioxin-6-yl-amine, and
- 2-(*tert*-butyldimethylsilanyloxymethyl)-2,3-dihydrobenzo[1,4]dioxin-6-yl-amine.

27- Compound of the formula IVa:



in which R^1 , R^2 and R^3 independently represent (C_1-C_6) alkyl; and NO_2 is located in position 6 or 7.

28- Compound of the formula IVa according to Claim 27, chosen from:

- *tert*-butyldimethyl(7-nitro-2,3-dihydrobenzo[1,4]dioxin-2-ylmethoxy)-silane;
- *tert*-butyldimethyl(6-nitro-2,3-dihydrobenzo[1,4]dioxin-2-ylmethoxy)-silane.

29- Pharmaceutical composition comprising one or more compounds of the formula I as defined in any one of Claims 1 to 12, in combination with one or more excipients.

30- Use of a compound of the formula I according to any one of Claims 1 to 12, for the preparation of a pharmaceutical composition for inhibiting microsomal triglyceride transfer protein (MTP).

31- Use according to Claim 29, characterised in that the said pharmaceutical composition is intended for the treatment of hypercholesterolaemia, hypertriglyceridaemia, hyperlipidaemia, pancreatitis, hyperglycaemia, obesity, atherosclerosis and diabetes-related dyslipidaemia.